No chin-scratcher: Kythera takes back global ATX-101 rights from Bayer
By Marie Powers
Tuesday, March 11, 2014
Five months after an upsized follow-on offering brought in $120 million and in the midst of preparing its new drug application (NDA) to the FDA for ATX-101, Kythera Biopharmaceuticals Inc. pulled off a crafty reacquisition of global rights for the aesthetic candidate from Bayer Healthcare’s Consumer Care Division, a unit of Bayer AG, of Leverkusen, Germany.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.